SCHEMBL3697487

SCHEMBL3697487

O=C1N=C(F)c2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CDC25B P30305 2/20 0.39
MAOA P21397 3/20 0.38
TDP2 O95551 3/20 0.38
PLCG1 P19174 2/20 0.38
CES1 P23141 2/20 0.38
APAF1 O14727 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CES2 O00748 1/20 0.38
TERT O14746 1/20 0.38
NPC1 O15118 1/20 0.38
PLIN1 O60240 1/20 0.38
S1PR4 O95977 1/20 0.38
LMNA P02545 1/20 0.38
PLA2G1B P04054 1/20 0.38
BCHE P06276 1/20 0.38
POLB P06746 1/20 0.38
PTPRC P08575 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3698764 0.76 MEN1 (0.36) MEN1KMT2ACDC25BMAOATDP2
SCHEMBL2359460 0.75 IDO1 (0.44) MEN1KMT2ACDC25BMAOATDP2
SCHEMBL29492985 0.75 CDC25B (0.39) MEN1KMT2ACDC25BMAOATDP2
SCHEMBL879050 0.75 CDC25B (0.39) MEN1KMT2ACDC25BMAOATDP2
Phthalimide SCHEMBL1388700 0.70 APAF1 (0.44) MEN1KMT2ACDC25BMAOATDP2
SCHEMBL31131321 0.70 LMNA (0.45) MEN1KMT2ACDC25BMAOATDP2
SCHEMBL2026326 0.70 MEN1 (0.39) MEN1KMT2ACDC25BMAOATDP2
SCHEMBL8026499 0.70 MEN1 (0.39) MEN1KMT2ACDC25BMAOATDP2
SCHEMBL149617 0.70 HSD11B1 (0.36) MEN1KMT2ACDC25BMAOATDP2
SCHEMBL112133 0.69 MEN1 (0.50) MEN1KMT2ACDC25BMAOATDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 MEN1 3158/4885KMT2A 561/4885CDC25B 478/4885
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR MEN1 1984/4885KMT2A 4282/4885CDC25B 3172/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR MEN1 1984/4885KMT2A 4282/4885CDC25B 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.